APSR2026-972

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP11-023
P65
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1243270-46904-APSR2026-972_433826.pdf
Format: PDF Only
09. Asthma
1

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

MUHAMMED ANAS AYOOB * ZAYED MILITARY HOSPITAL PULMONARY MEDICINE ABU DHABI United Arab Emirates
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
MUHAMMED ANAS
AYOOB
dranazm@gmail.com
+971547891323
41-50
United Arab Emirates
Original Research
Predictive Value of Blood Eosinophil Count and FeNO for Clinical Response to Anti-IL-5 and Anti-IL-4Rα Biologic Therapies in Severe Asthma
Maximum 25 words
Abstract Content
Severe asthma is a heterogeneous inflammatory airway disease characterised by frequent exacerbations, reduced quality of life, and increased healthcare utilisation. Blood eosinophil count and fractional exhaled nitric oxide (FeNO) are commonly used biomarkers to guide biologic therapy selection; however, their comparative predictive value across different biologic classes remains unclear. This study assessed the predictive performance of blood eosinophils and FeNO for clinical response to anti–IL-5 and anti–IL-4Rα biologic therapies in severe asthma.
This retrospective real-world cohort study included 95 adults with severe asthma treated with mepolizumab (n=32), benralizumab (n=24), or dupilumab (n=39) at a tertiary care centre in the United Arab Emirates from 2020 to 2025. Baseline biomarkers measured were blood eosinophils, FeNO, and serum total IgE. Clinical outcomes assessed over 12 months included Asthma Control Test (ACT) score, forced expiratory volume in one second (FEV1), annualised exacerbation frequency, adverse events, and medication possession ratio. Receiver operating characteristic analysis and multivariable logistic regression were used to evaluate biomarker predictive performance.
Biologic therapy resulted in significant improvements in ACT score (12.0 vs 18.2), FEV1 (2.67 vs 2.81 L), and annual exacerbation frequency (2.42 vs 1.07; all p<0.001). FeNO exhibited superior predictive performance for clinical response (AUC 0.685) compared to blood eosinophils (AUC 0.467). Patients with baseline FeNO ≥25 ppb demonstrated significantly higher ACT response rates than those with lower FeNO levels (87.3% vs 65.0%; p=0.0127). Blood eosinophils showed limited discriminative power across outcomes. Combined phenotype-based biomarker stratification identified higher response rates among patients with elevated eosinophil and FeNO levels who received anti–IL-5 therapy. Serum IgE contributed minimal additional predictive value.
Biologic therapy resulted in significant clinical improvement in severe asthma. FeNO was the most effective biomarker for predicting treatment response, while blood eosinophils and serum IgE demonstrated limited predictive utility when used alone. Multidimensional biomarker and phenotype-based approaches may enhance precision in selecting biological therapies for the management of severe asthma.
 
 
 
 
 
Yes
Yes
https://storage.unitedwebnetwork.com/files/1285/1243270-37089-responserate_399330.png
JPG or JPEG or PNG format ONLY
biologics in asthma, feno, severe asthma
maximum 3 keywords and no abbreviations, separated by commas
 
330